Caris Life Sciences and Xencor Entered Target Discovery Collaboration and License Agreement for Novel XmAb Bispecific Antibodies; Caris to Receive Upfront Payment and Be Eligible to Receive Up to ~$120M in License Fees, Discovery, Development, Regulato…
Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
Xencor To Report Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors At Annual Meeting of the American Society of Clinical Oncology On June 5
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from
Piper Sandler Maintains Overweight on Xencor, Lowers Price Target to $42
Piper Sandler analyst Edward Tenthoff maintains Xencor (NASDAQ:XNCR) with a Overweight and lowers the price target from $66 to $42.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Xencor’s Earnings Outlook
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Xencor will report an earnings per share (EPS) of $-0.60.